Abstract 765 Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol(Veletri®): 6-months, open label, observational, non-interventional study

Clin Res Cardiol (2022). https://doi.org/10.1007/s00392-022-02002-5
Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol(Veletri®): 6-months, open label, observational, non-interventional study
J. Degering¹, S. Harutyunova², N. Benjamin¹, P. Xanthouli¹, C. Eichstaedt², B. Egenlauf¹, R. Seeger-Zybok³, E. Grünig²
¹Pneumologie und Beatmungsmedizin / Zentrum für Pulmonale Hypertonie, Thoraxklinik - Heidelberg gGmbH, Heidelberg; ²Thoraxklinik, Universitätsklinikum Heidelberg, Heidelberg; ³Zentrum für Pulmonale Hypertonie, Thoraxklinik - Heidelberg gGmbH, Heidelberg;
Background: Veletri®, a new epoprostenol formulation, provides better drug stability and improved clinical use compared to previous epoprostenol formulations. This study aims to expand clinical experience in the use of Veletri®, especially with regard to tolerability, safety and survival. Method: Pulmonary arterial hypertension (PAH) patients at high risk despite double oral combination therapy were consecutively included in this prospective, open label, observational, non-interventional study. Clinical data were assessed at baseline, after 3 and 6 months. Adverse events (AE´s) and serious adverse events (SAE´s) were documented. Survival of all patients was assessed at the end of study.Results: Overall, 15 patients (60±13.7 years, WHO functional class III-IV, severely impaired right ventricular pump function, mean pulmonary arterial pressure 54.8±8.9 mmHg, mean pulmonary vascular resistance 4.4±0.7 (median 3.8) Wood Units) were enrolled and treated with a mean dosage of 7.9±3.9 (median 7.5) ng/kg/min. Ten patients completed the study (treatment withdrawal n=2, death n=3). After a mean follow-up of 19.1±13.5 (median 18.0) months, seven patients died and three were listed for lung transplantation. Seven AEs (nausea n=3, diarrhea n=1, flushing n=2, headaches n=1) and three SAEs (catheter infection n=2, catheter occlusion n=1) were related to Veletri®. The 1- and 2-year survival rate was 73.3% and 52.4%, respectively. Conclusion: The study showed that safety and tolerability of epoprostenol (Veletri®) was comparable to previous prostacyclin formulations and was feasible in most patients. The clinically determined maximum tolerable dosage was lower than dosages reported in the literature. Survival was as expected in these severely impaired patients.
https://dgk.org/kongress_programme/jt2022/aP889.html